![]() A 2017 Cochrane review found it is as safe and effective as first line or second line endocrine therapy. Medical uses Breast cancer įulvestrant is used for the treatment of hormone receptor positive metastatic breast cancer or locally advanced unresectable disease in postmenopausal women it is given by injection. įulvestrant was approved for medical use in the United States in 2002. It works by binding to the estrogen receptor and destabilizing it, causing the cell's normal protein degradation processes to destroy it. įulvestrant is a selective estrogen receptor degrader (SERD) and was first-in-class to be approved. Fulvestrant, sold under the brand name Faslodex among others, is a medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.
0 Comments
Leave a Reply. |